Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Pharmaceuticals
- Biotechnology
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26434
License Grant
The University Licensor hereby grants to Licensee an exclusive license under both Patent Rights and Technology Rights to manufacture, have manufactured, use, and/or sell Licensed Products within Licensed Territory for use within Licensed Field and hereby grants to Licensee an exclusive license under Linker Patent Rights and Linker Technology Rights to manufacture, have manufactured, use, and/or sell Licensed Products within Licensed Territory for use within Licensed Field, with the exception of those uses related to immunotoxins directed against neoplastic cells, in which case the license granted to Licensee herein shall be non-exclusive.
License Property
These patents and patent applications cover the generic idea of clotting tumor vasculature as a means cancer therapy. The concepts covered by these patents and patent applications include clotting tumor blood vessels either by killing the tumor blood vessels which leads to clotting or by directly clotting the blood vessels by targeting natural clotting proteins to the tumor blood vessels.
Field of Use
Licensed Field shall mean targeting compounds to or acting on tumor vasculature or any other components of a tumor for therapeutic or diagnostic use.
IPSCIO Record ID: 2250
License Grant
The VTA technology was acquired in April of 1997 through the Licensee's acquisition of the Licensor's Phase I Study. The Licensee has entered into several license agreements in order to acquire all of the rights which it deems necessary to proceed with its vascular targeting agent ('VTA's') technology.
License Property
VTA’s act by destroying the vasculature of solid tumors. VTA’s are multifunctional molecules that target the capillaries and blood vessels of solid tumors. Once there, these agents block the flow of oxygen and nutrients to the underlying tissue by creating a blood clot to the tumor. Within hours of the clots formation, the tumor begins to die and necrotic regions are formed. Since every tumor in excess of 2mm in size forms an expanding vascular network during tumor growth, VTA’s could be effective against all types of solid tumors.
IPSCIO Record ID: 227271
License Grant
The University grants to Licensee
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.
The agreement is exclusive except for the non-exclusive license granted to the U.S. government
License Property
The patents are for Method and Composition for Angiogenesis Inhibition, Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth, and, Generation And Use Of MABXL313 To Inhibit
Angiogenesis And Tumor Growth In Vivo.
2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth
2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo
Anti-Angiogenesis for the Treatment of Cancer
In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.
Field of Use
Field of Use shall mean any field of use.
IPSCIO Record ID: 29195
License Grant
Board hereby grants to Licensee an exclusive license under both Coagulation Patent Rights and Coagulation Technology Rights to manufacture, have manufactured, use, and/or sell Licensed Products.
License Property
Coagulation Technology Rights shall mean Board’s rights in any technical information, know-how, process, procedure, composition, or device, method, formula, protocol, technique, software, design, drawing, data, biological and other materials which are useful in targeting therapeutic and diagnostic compounds to tumor vasculature in humans and which are not covered by Coagulation Patent Rights but which are necessary or useful for practicing any inventions at any time covered by Coagulation Patent Rights.
Field of Use
Licensed Field shall mean targeting compounds to or acting on tumor vasculature or any other component of a tumor for therapeutic or diagnostic use.
IPSCIO Record ID: 243413
License Grant
Licensor grants an exclusive, worldwide license to Licensors entire interest in and to Licensed Patents within the Field to make, have made, use, import, have imported, sell, offer for sale and otherwise exploit and distribute Licensed Products, and, practice any method, process or procedure included within the Licensed Patents; and to have any of the foregoing performed on its behalf by a third party.
License Property
The patents are for Vascular Targeting Agents and targeting vascular endothelial growth factor or VEGF.
The VTA technology is a proprietary therapeutic platform designed to specifically target tumor vasculature and subsequently destroy the tumor with various attached therapeutic agents.
Field of Use
Field shall mean vascular endothelial growth factor (VEGF), in the native, mutants and variants thereof, conjugated to cytotoxic drugs, toxins, radionuclides or photodynamic therapy agents for targeting tumors and cells expressing VEGF receptors and tumor blood vessels for therapy of cancer and blood vessel proliferative disorders, including but not limited to macular degeneration, diabetic retinopathy, and pannus formation.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
